# Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent

Source: https://onco.cc/trials/nct03564340/  
OnCo record `nct03564340` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cemiplimab, Tocilizumab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers is a phase 1/2 interventional study registered as NCT03564340 by Regeneron Pharmaceuticals, with 890 participants planned, started 2018-05-21 and due to reach its primary completion in 2027-05-10. Interventions recorded: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab. Conditions listed: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03564340
- Phase: 1/2
- Setting: A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 890

## Sources

- ClinicalTrials.gov NCT03564340: https://clinicaltrials.gov/study/NCT03564340

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/), [Ubamatamab](https://onco.cc/drugs/ubamatamab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct03564340.json